GGS
VRTX icon

Galvin Gaustad & Stein’s Vertex Pharmaceuticals VRTX Stock Holding History

Galvin Gaustad & Stein’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
29,760
-5,473
-16% -$2.43M 1.09% 31
2026
Q1 		$15.7M Buy
35,233
+924
+3% +$431K 1.26% 27
2025
Q4 		$15.6M Buy
34,309
+1,167
+4% +$503K 1.21% 32
2025
Q3 		$13M Buy
33,142
+10,252
+45% +$4.28M 1.05% 43
2025
Q2 		$10.2M Buy
22,890
+1,529
+7% +$705K 0.88% 49
2025
Q1 		$10.4M Sell
21,361
-367
-2% -$171K 0.93% 48
2024
Q4 		$8.75M Sell
21,728
-233
-1% -$108K 0.78% 52
2024
Q3 		$10.2M Sell
21,961
-14,724
-40% -$7.07M 0.91% 45
2024
Q2 		$17.2M Buy
36,685
+9,280
+34% +$4.03M 1.6% 27
2024
Q1 		$11.5M Buy
27,405
+6,358
+30% +$2.69M 1.05% 41
2023
Q4 		$8.56M Buy
+21,047
New +$7.78M 0.8% 46

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Galvin Gaustad & Stein's VRTX Position: Q2 2026 in Review

Galvin Gaustad & Stein reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, selling an estimated $2.43M and leaving 29,760 shares worth $14.8M. The position accounts for 1.09% of the portfolio, ranked #31.

Galvin Gaustad & Stein first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.2M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Galvin Gaustad & Stein held 29,760 shares of Vertex Pharmaceuticals worth $14.8M as of Q2 2026.
  • Galvin Gaustad & Stein sold 5,473 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.43M.
  • Vertex Pharmaceuticals made up 1.09% of Galvin Gaustad & Stein's portfolio in Q2 2026, its #31 holding.
  • Galvin Gaustad & Stein first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Galvin Gaustad & Stein's Vertex Pharmaceuticals position peaked at $17.2M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q2 2026, filed 29 Jul 2026.